CoChat

Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

BACKGROUND: gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models. METHODS: -mutant NSCLC. Three cohorts were defined according to previous therapy: cohort D comprised previously treated patients who had not received HER2-targeted therapy; cohort E, patients who had previously received HER2-directed antibody-drug conjugates; and cohort F, patients who had not previously received treatment. The primary end point was an objective response, as assessed by blinded independent central review. Secondary end points were duration of response and progression-free survival. RESULTS: A total of 209 patients received sevabertinib (as of June 27, 2025, the data-cutoff date); the median duration of follow-up was 13.8 months in cohort D, 11.7 months in cohort E, and 9.9 months in cohort F. Among 81 patients in cohort D, an objective response was observed in 64% (95% confidence interval [CI], 53 to 75); the median duration of response was 9.2 months (95% CI, 6.3 to 13.5), and the median progression-free survival was 8.3 months (95% CI, 6.9 to 12.3). Among 55 patients in cohort E, an objective response was observed in 38% (95% CI, 25 to 52); the median duration of response was 8.5 months, and the median progression-free survival was 5.5 months. Among 73 patients in cohort F, an objective response was observed in 71% (95% CI, 59 to 81), and the median duration of response was 11.0 months; data on progression-free survival were immature. Grade 3 or higher drug-related adverse events occurred in 31% of the patients. The most common adverse event was diarrhea (in 84 to 91%), with diarrhea of grade 3 or higher occurring in 5 to 23%. Treatment was discontinued by 3% of the patients owing to drug-related adverse events. CONCLUSIONS: -mutant NSCLC. Diarrhea was the most common adverse event. (Funded by Bayer; SOHO-01 ClinicalTrials.gov number, NCT05099172.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2511065

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 34 references

Cited by

See all 70

Metadata

Authors
Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., Shinno, Y., Daniele, G., Yang, T.-Y., Kim, H. R., Ruiter, G., Zhao, J., Novello, S., Miao, L., Jänne, P. A., Goto, K., Rüttinger, D., Descamps, T., Brase, J. C., Bao, W., Li, R., Brega, N., Grassi, P., Girard, N., & Tan, D. S.-W.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Seoul National University (KR)
  • Chinese University of Hong Kong (HK)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • National University of Singapore (SG)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Sir Run Run Shaw Hospital (CN)
  • Shanghai Jiao Tong University (CN)
  • Wuhan Union Hospital (CN)
  • Central South University (CN)
  • National Cancer Center Hospital (JP)
  • Agostino Gemelli University Polyclinic (IT)
  • Taichung Veterans General Hospital (TW)
  • Yonsei University (KR)
  • The Netherlands Cancer Institute (NL)
  • Peking University Cancer Hospital (CN)
  • Ospedale San Luigi Gonzaga (IT)
  • Nanjing Drum Tower Hospital (CN)
  • Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute, Boston
  • National Cancer Center Hospital East, Kashiwa, Japan
  • Bayer (Germany) (DE)
  • Bayer (United Kingdom) (GB)
  • Bayer (Switzerland) (CH)
  • Bayer (United States) (US)
  • Bayer (Italy) (IT)
  • Institut Curie (FR)
Venue
New England Journal of Medicine
Published
2025-11-06
Volume
393
Issue
18
Pages
1819-1832
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4415295860
Cited by
70
References
34
Citations by year
2026: 65 · 2025: 5
FWCI
45.69
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders
Bayer
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
HER2-mutant non-small cell lung cancer, HER2 tyrosine kinase inhibitor, HER2-targeted therapy, antibody-drug conjugates, objective response rate, progression-free survival, diarrhea adverse event, advanced non-small cell lung cancer, oral tyrosine kinase inhibitor, previously treated patients, treatment-naive patients, duration of response, treatment discontinuation
MeSH terms
Progression-Free Survival, Tyrosine Kinase Inhibitors, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Diarrhea, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Time Factors, Erb-b2 Receptor Tyrosine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2511065
The paper
Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., Shinno, Y., Daniele, G., Yang, T.-Y., Kim, H. R., Ruiter, G., Zhao, J., Novello, S., Miao, L., Jänne, P. A., . . . Tan, D. S.-W. (2025). Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2511065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.